In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications.The proposed ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...

for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5.

Data from the ANCHOR and SWIFT trials are being used to support regulatory filings for depemokimab in various nations for the treatment of asthma with type 2 inflammation and CRSwNP. The antibody ...